首页 > 最新文献

Cardiovascular Revascularization Medicine最新文献

英文 中文
Predictors of extracorporeal membrane oxygenation utilization and survival during cardiopulmonary resuscitation in out and in-hospital cardiac arrest 院外和院内心脏骤停心肺复苏期间体外膜氧合利用和生存的预测因素。
IF 1.9 Q3 CARDIAC & CARDIOVASCULAR SYSTEMS Pub Date : 2026-01-01 DOI: 10.1016/j.carrev.2025.05.008
Laith Alhuneafat , Fares Ghanem , Milos Brankovic , Omar Obeidat , Gaspar Del Rio Pertuz , Alejandra Gutierrez , Ahmad Jabri , Dil Patel , Jason Bartos , Andrea Elliott

Introduction

Extracorporeal membrane oxygenation during cardiopulmonary resuscitation (ECPR) has shown promise in managing both out-of-hospital cardiac arrest (OHCA) and in-hospital cardiac arrest (IHCA).

Methods

We analyzed hospital discharge records from the National Inpatient Sample of adult individuals who underwent ECPR between 2016 and 2020. Multivariable regression analyses were conducted to identify factors influencing ECPR utilization and survival.

Results

Among 1,585,960 patients (901,470 OHCA, 684,490 IHCA), ECPR utilization rates were 1 % for OHCA and 1.4 % for IHCA, with inpatient mortality rates of 52 % and 67 %, respectively. In OHCA, ECPR was more likely in patients from higher-income areas, those with Medicaid/private insurance, systolic heart failure, shockable rhythms, and Hispanic/other races but less likely in those over 65, with patients with history of atrial fibrillation, diabetes, cerebrovascular accident, or COPD. In IHCA, ECPR was more common in larger hospitals, higher-income areas, and those with private insurance but less frequent in Black patients, those over 65, or with prior cerebrovascular accidents, COPD, diabetes, or end-stage renal disease. In OHCA ECPR, Asian race (aOR: 2.31), diabetes (aOR: 1.29), and liver disease (aOR: 1.77) predicted mortality, while shockable rhythms (aOR: 0.75), systolic heart failure (aOR: 0.67), and treatment in southern states (aOR: 0.72) predicted survival. In IHCA ECPR, acute myocardial infarction (aOR: 0.73) and private insurance (aOR: 0.63) were associated with improved survival, whereas liver disease (aOR: 1.59) predicted higher mortality.

Conclusion

We highlight the selective nature of ECPR utilization between OHCA and IHCA and the distinct survival predictors in each setting. Further research is needed to refine selection criteria and optimize patient outcomes.
心肺复苏(ECPR)期间的体外膜氧合在管理院外心脏骤停(OHCA)和院内心脏骤停(IHCA)方面显示出前景。方法:我们分析了2016年至2020年期间接受ECPR的全国住院患者样本的出院记录。多变量回归分析确定影响ECPR使用和生存的因素。结果:1,585,960例患者(901,470例OHCA, 684,490例IHCA)中,OHCA和IHCA的ECPR使用率分别为1%和1.4%,住院死亡率分别为52%和67%。在OHCA中,ECPR更可能发生在高收入地区、有医疗补助/私人保险、收缩期心力衰竭、震荡性心律和西班牙裔/其他种族的患者中,但在65岁以上、有房颤、糖尿病、脑血管事故或COPD病史的患者中发生的可能性较小。在IHCA中,ECPR在大医院、高收入地区和有私人保险的患者中更为常见,但在黑人患者、65岁以上患者、或既往有脑血管事故、慢性阻塞性肺病、糖尿病或终末期肾脏疾病的患者中较少发生。在OHCA ECPR中,亚洲种族(aOR: 2.31)、糖尿病(aOR: 1.29)和肝病(aOR: 1.77)预测死亡率,而休克节律(aOR: 0.75)、收缩期心力衰竭(aOR: 0.67)和南部各州的治疗(aOR: 0.72)预测生存率。在IHCA ECPR中,急性心肌梗死(aOR: 0.73)和私人保险(aOR: 0.63)与生存率的提高相关,而肝病(aOR: 1.59)预示着更高的死亡率。结论:我们强调了在OHCA和IHCA之间使用ECPR的选择性,以及每种情况下不同的生存预测因素。需要进一步的研究来完善选择标准和优化患者的结果。
{"title":"Predictors of extracorporeal membrane oxygenation utilization and survival during cardiopulmonary resuscitation in out and in-hospital cardiac arrest","authors":"Laith Alhuneafat ,&nbsp;Fares Ghanem ,&nbsp;Milos Brankovic ,&nbsp;Omar Obeidat ,&nbsp;Gaspar Del Rio Pertuz ,&nbsp;Alejandra Gutierrez ,&nbsp;Ahmad Jabri ,&nbsp;Dil Patel ,&nbsp;Jason Bartos ,&nbsp;Andrea Elliott","doi":"10.1016/j.carrev.2025.05.008","DOIUrl":"10.1016/j.carrev.2025.05.008","url":null,"abstract":"<div><h3>Introduction</h3><div>Extracorporeal membrane oxygenation during cardiopulmonary resuscitation (ECPR) has shown promise in managing both out-of-hospital cardiac arrest (OHCA) and in-hospital cardiac arrest (IHCA).</div></div><div><h3>Methods</h3><div>We analyzed hospital discharge records from the National Inpatient Sample of adult individuals who underwent ECPR between 2016 and 2020. Multivariable regression analyses were conducted to identify factors influencing ECPR utilization and survival.</div></div><div><h3>Results</h3><div><span><span>Among 1,585,960 patients (901,470 OHCA, 684,490 IHCA), ECPR utilization rates were 1 % for OHCA and 1.4 % for IHCA, with inpatient mortality rates of 52 % and 67 %, respectively. In OHCA, ECPR was more likely in patients from higher-income areas, those with Medicaid/private insurance, </span>systolic heart failure<span>, shockable rhythms, and Hispanic/other races but less likely in those over 65, with patients with history of atrial fibrillation, diabetes, cerebrovascular accident, or </span></span>COPD<span>. In IHCA, ECPR was more common in larger hospitals, higher-income areas, and those with private insurance but less frequent in Black patients, those over 65, or with prior cerebrovascular accidents, COPD<span><span>, diabetes, or end-stage renal disease. In OHCA ECPR, Asian race (aOR: 2.31), diabetes (aOR: 1.29), and liver disease (aOR: 1.77) predicted mortality, while shockable rhythms (aOR: 0.75), systolic heart failure (aOR: 0.67), and treatment in southern states (aOR: 0.72) predicted survival. In IHCA ECPR, </span>acute myocardial infarction (aOR: 0.73) and private insurance (aOR: 0.63) were associated with improved survival, whereas liver disease (aOR: 1.59) predicted higher mortality.</span></span></div></div><div><h3>Conclusion</h3><div>We highlight the selective nature of ECPR utilization between OHCA and IHCA and the distinct survival predictors in each setting. Further research is needed to refine selection criteria and optimize patient outcomes.</div></div>","PeriodicalId":47657,"journal":{"name":"Cardiovascular Revascularization Medicine","volume":"82 ","pages":"Pages 111-119"},"PeriodicalIF":1.9,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144112291","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
What is the confusion about diversity, equity, and inclusion? 对多样性、公平和包容性的困惑是什么?
IF 1.9 Q3 CARDIAC & CARDIOVASCULAR SYSTEMS Pub Date : 2026-01-01 DOI: 10.1016/j.carrev.2025.12.013
Spencer B. King III
{"title":"What is the confusion about diversity, equity, and inclusion?","authors":"Spencer B. King III","doi":"10.1016/j.carrev.2025.12.013","DOIUrl":"10.1016/j.carrev.2025.12.013","url":null,"abstract":"","PeriodicalId":47657,"journal":{"name":"Cardiovascular Revascularization Medicine","volume":"82 ","pages":"Pages 145-146"},"PeriodicalIF":1.9,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145806075","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Hemocompatibility related complications in Impella 5+ patients treated with Bivalirudin and dual antiplatelet therapy: a SHEAR score evaluation 使用比伐鲁定和双重抗血小板治疗的Impella 5+患者血液相容性相关并发症:SHEAR评分评估
IF 1.9 Q3 CARDIAC & CARDIOVASCULAR SYSTEMS Pub Date : 2026-01-01 DOI: 10.1016/j.carrev.2025.05.003
Marta Bandini , Serena Querio , Elena Utzeri , Astrid Cardinale , Giulia Maj , Andrea Audo , Federico Pappalardo

Background

The surgical Impella 5.0 and 5.5 (5+) provide greater and more durable hemodynamic support than Impella CP in patients with cardiogenic shock. The concomitant need for DAPT on top of systemic anticoagulation might increase the risk for hemocompatibility-related adverse events.

Methods

13 patients who underwent primary PCI and Impella 5+ support and were treated with DAPT and Bivalirudin. We evaluated adverse events (AEs) and hemocompatibility-related complications according to the SHEAR score.

Results

Median duration of Impella 5+ support was 14 ± 32 days. At baseline, all patients had risk for bleeding because of DAPT (SHEAR A); moreover, 2 patients suffered from thrombocytopenia. None presented risk factors for thrombosis. The highest total SHEAR score was 6 in 2 patients, three patients had a total SHEAR score of 3, three patients had a total SHEAR score of 2, 5 patients had a total SHEAR score of 1. Both bleeding and thrombotic events were most frequent within the first 48 h of support, and bleeding events had a greater role in determining the hemocompatibilty score. No patient suffered from clinically relevant hemocompatibility-related adverse events.

Conclusions

In conclusion, we report a low rate of thrombotic and hemorrhagic events in a cohort of AMI-CS patients requiring Impella 5+ support and treated with bivalirudin and DAPT, according to the SHEAR score classification. This is further confirmed by the ability of the SHEAR score to add multiple events that can occur during prolonged support. Further studies are urgently needed to confirm this new approach in tMCS.
背景:在心源性休克患者中,外科Impella 5.0和5.5(5+)比Impella CP提供更大、更持久的血流动力学支持。在全身抗凝之上同时需要DAPT可能会增加血液相容性相关不良事件的风险。方法:13例首次行PCI + Impella 5+支持,DAPT联合比伐鲁定治疗的患者。我们根据SHEAR评分评估不良事件(ae)和血液相容性相关并发症。结果:Impella 5+支架的中位持续时间为14±32天。在基线时,所有患者都有因DAPT而出血的风险(SHEAR A);2例出现血小板减少症。没有出现血栓形成的危险因素。2例患者总SHEAR评分最高为6分,3例患者总SHEAR评分为3分,3例患者总SHEAR评分为2分,5例患者总SHEAR评分为1分。出血和血栓事件在支持的前48小时内最常见,出血事件在决定血液相容性评分中起着更大的作用。没有患者出现临床相关的血液相容性不良事件。结论:根据SHEAR评分分类,我们报告了一组需要Impella 5+支持并接受比伐鲁定和DAPT治疗的AMI-CS患者的血栓和出血事件发生率较低。SHEAR评分能够将延长支持期间可能发生的多个事件相加,这进一步证实了这一点。迫切需要进一步的研究来证实这种新方法在tMCS中的应用。
{"title":"Hemocompatibility related complications in Impella 5+ patients treated with Bivalirudin and dual antiplatelet therapy: a SHEAR score evaluation","authors":"Marta Bandini ,&nbsp;Serena Querio ,&nbsp;Elena Utzeri ,&nbsp;Astrid Cardinale ,&nbsp;Giulia Maj ,&nbsp;Andrea Audo ,&nbsp;Federico Pappalardo","doi":"10.1016/j.carrev.2025.05.003","DOIUrl":"10.1016/j.carrev.2025.05.003","url":null,"abstract":"<div><h3>Background</h3><div><span><span>The surgical Impella 5.0 and 5.5 (5+) provide greater and more durable hemodynamic support than Impella CP in patients with </span>cardiogenic shock<span>. The concomitant need for DAPT on top of systemic </span></span>anticoagulation<span> might increase the risk for hemocompatibility-related adverse events.</span></div></div><div><h3>Methods</h3><div><span>13 patients who underwent primary PCI and Impella 5+ support and were treated with </span>DAPT<span> and Bivalirudin. We evaluated adverse events (AEs) and hemocompatibility-related complications according to the SHEAR score.</span></div></div><div><h3>Results</h3><div><span>Median duration of Impella 5+ support was 14 ± 32 days. At baseline, all patients had risk for bleeding because of DAPT (SHEAR A); moreover, 2 patients suffered from </span>thrombocytopenia. None presented risk factors for thrombosis. The highest total SHEAR score was 6 in 2 patients, three patients had a total SHEAR score of 3, three patients had a total SHEAR score of 2, 5 patients had a total SHEAR score of 1. Both bleeding and thrombotic events were most frequent within the first 48 h of support, and bleeding events had a greater role in determining the hemocompatibilty score. No patient suffered from clinically relevant hemocompatibility-related adverse events.</div></div><div><h3>Conclusions</h3><div>In conclusion, we report a low rate of thrombotic and hemorrhagic events in a cohort of AMI-CS patients requiring Impella 5+ support and treated with bivalirudin and DAPT, according to the SHEAR score classification. This is further confirmed by the ability of the SHEAR score to add multiple events that can occur during prolonged support. Further studies are urgently needed to confirm this new approach in tMCS.</div></div>","PeriodicalId":47657,"journal":{"name":"Cardiovascular Revascularization Medicine","volume":"82 ","pages":"Pages 102-108"},"PeriodicalIF":1.9,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144054669","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Evaluation of the CorPath-GRX technIQ automated movements during robotic-PCI (NAVIGATE GRX study) 机器人pci手术期间CorPath-GRX technIQ自动运动的评估(NAVIGATE GRX研究)。
IF 1.9 Q3 CARDIAC & CARDIOVASCULAR SYSTEMS Pub Date : 2026-01-01 DOI: 10.1016/j.carrev.2025.05.027
Rossella Ruggiero , Arif A. Khokhar , Zbigniew Siudak , Adriana Zlahoda-Huzior , Aleksander Zelias , Dariusz Dudek

Background

The second-generation Corepath GRX system utilized smart automation technology, known as TechnIQ automation, to produce predictable and consistent movements typically executed by operators during manual PCI.

Aim

The aim of our study was to evaluate the safety and efficacy of TechnIQ automated movements in clinical practice.

Methods

Patients with CAD and indication for PCI were randomized to underwent to Robotic-PCI with either TechnIQ automated movements ON or OFF. Safety endpoint was defined as a composite of MACE (Cardiac Death, Target Vessel myocardial infarction (TV-MI), and Target Vessel Revascularization (TVR)) and Major Angiographic Complications (perforation or flow-limiting dissection). Efficacy endpoint was defined as need for manual conversion and final angiographic TIMI flow 3. Total procedural time, total contrast administration, total fluoroscopy time and total DAP exposure were also evaluated.

Results

A total of 49 patients (mean age 68.2 ± 7.5 years; 30.6 % female) underwent to PCI on 55 vessels (27 with TechnIQ ON, 28 with TechnIQ OFF). No cases of Cardiac Death, TV-MI and TVR were observed. Only one case of flow limiting dissection occurred in the TechnIQ OFF group during manual cannulation, and one case of non-fatal stroke occurred in the TechnIQ ON group. Finally, the unplanned manual conversion occurred for 6 patients in the TechnIQ ON group (22 %) and 5 patients in the TechnIQ OFF group (18 %).

Conclusions

This study demonstrates the safety of using smart automation algorithm (TechnIQ automation) during R-PCI, without an increased need for unplanned manual conversion.
背景:第二代Corepath GRX系统利用人工智能技术,被称为TechnIQ自动化,产生可预测和一致的动作,通常由操作员在手动PCI期间执行。目的:我们研究的目的是评估临床实践中TechnIQ自动运动的安全性和有效性。方法:有CAD和PCI指征的患者随机接受Robotic-PCI,其中TechnIQ自动运动ON或OFF。安全终点定义为MACE(心源性死亡、靶血管心肌梗死(TV-MI)和靶血管重建术(TVR))和主要血管造影并发症(穿孔或限流夹层)的综合。疗效终点定义为需要人工转换和最终血管造影TIMI流量3。同时评估总手术时间、总造影剂给药时间、总透视时间和总DAP暴露时间。结果:49例患者(平均年龄68.2±7.5岁;30.6%的女性)接受了55条血管的PCI(27条为on, 28条为OFF)。无心脏性死亡、TV-MI、TVR病例。在手工插管过程中,TechnIQ OFF组仅发生1例限流夹层,TechnIQ ON组发生1例非致死性脑卒中。最后,在TechnIQ ON组中有6名患者(22%)和TechnIQ OFF组中有5名患者(18%)发生了计划外的人工转换。结论:本研究证明了在R-PCI期间使用人工智能算法(TechnIQ自动化)的安全性,而不需要增加计划外的人工转换。
{"title":"Evaluation of the CorPath-GRX technIQ automated movements during robotic-PCI (NAVIGATE GRX study)","authors":"Rossella Ruggiero ,&nbsp;Arif A. Khokhar ,&nbsp;Zbigniew Siudak ,&nbsp;Adriana Zlahoda-Huzior ,&nbsp;Aleksander Zelias ,&nbsp;Dariusz Dudek","doi":"10.1016/j.carrev.2025.05.027","DOIUrl":"10.1016/j.carrev.2025.05.027","url":null,"abstract":"<div><h3>Background</h3><div>The second-generation Corepath GRX system utilized smart automation technology, known as TechnIQ automation, to produce predictable and consistent movements typically executed by operators during manual PCI.</div></div><div><h3>Aim</h3><div>The aim of our study was to evaluate the safety and efficacy of TechnIQ automated movements in clinical practice.</div></div><div><h3>Methods</h3><div>Patients with CAD and indication for PCI were randomized to underwent to Robotic-PCI with either TechnIQ automated movements ON or OFF. Safety endpoint was defined as a composite of MACE (Cardiac Death, Target Vessel myocardial infarction (TV-MI), and Target Vessel Revascularization<span> (TVR)) and Major Angiographic Complications (perforation or flow-limiting dissection). Efficacy endpoint was defined as need for manual conversion and final angiographic TIMI<span><span> flow 3. Total procedural time, total contrast administration, total fluoroscopy time and total </span>DAP exposure were also evaluated.</span></span></div></div><div><h3>Results</h3><div>A total of 49 patients (mean age 68.2 ± 7.5 years; 30.6 % female) underwent to PCI on 55 vessels (27 with TechnIQ ON, 28 with TechnIQ OFF). No cases of Cardiac Death, TV-MI and TVR were observed. Only one case of flow limiting dissection occurred in the TechnIQ OFF group during manual cannulation, and one case of non-fatal stroke occurred in the TechnIQ ON group. Finally, the unplanned manual conversion occurred for 6 patients in the TechnIQ ON group (22 %) and 5 patients in the TechnIQ OFF group (18 %).</div></div><div><h3>Conclusions</h3><div>This study demonstrates the safety of using smart automation algorithm (TechnIQ automation) during R-PCI, without an increased need for unplanned manual conversion.</div></div>","PeriodicalId":47657,"journal":{"name":"Cardiovascular Revascularization Medicine","volume":"82 ","pages":"Pages 23-28"},"PeriodicalIF":1.9,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144235571","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Percutaneous renal denervation in the management of kidney-related pain syndromes: a case series 经皮肾去神经支配治疗肾相关疼痛综合征:一个病例系列。
IF 1.9 Q3 CARDIAC & CARDIOVASCULAR SYSTEMS Pub Date : 2026-01-01 DOI: 10.1016/j.carrev.2025.04.041
K.A. Saville , V.J.M. Zeijen , R. Zietse , M. Salih , D.A. Hesselink , J. Daemen

Introduction

Positive effects on pain reduction following renal denervation (RDN) have been described in patients with kidney-related pain syndromes, yet data on the safety and efficacy of redo RDN procedures are limited.

Methods

Consecutive patients with a history of chronic loin pain, hypertension and preserved renal function (eGFR ≥40 ml/min) scheduled for RDN were included. Changes in perceived pain, opioid and antihypertensive medication use, and blood pressure were prospectively assessed 3 months after each procedure.

Results

Two patients presented with a history of Autosomal Dominant Polycystic Kidney Disease (n = 2) and one with Loin Pain Hematuria Syndrome (n = 1). Two patients underwent a redo RDN. After the initial procedures, a reduction in perceived pain, along with a 50 % and 75 % reduction in the daily dosage of opioids, was observed in two patients. One patient showed no reduction in perceived pain or opioid use and underwent a redo procedure after 3 years, again with no reduction in perceived pain or opioid use. One patient who initially responded returned at 2 years with recurrent symptoms and underwent a redo procedure. After 3 months, a significant improvement in pain and opioid use was observed. Mean 24-hour systolic blood pressure decreased in all patients and after each procedure with a mean decrease of 12 mmHg. No adverse events were observed.

Conclusion

In hypertensive patients with kidney-related pain syndromes, percutaneous RDN may be considered as an alternative treatment option to reduce pain severity and improve blood pressure control. Redo procedures may be considered in patients with recurrent symptoms after an initial response.
导读:肾相关疼痛综合征患者行肾去神经支配(RDN)后疼痛减轻的积极作用已有报道,但重行肾去神经支配(RDN)手术的安全性和有效性数据有限。方法:纳入有慢性腰痛、高血压和保留肾功能(eGFR≥40 ml/min)计划进行RDN的连续患者。每次手术后3个月前瞻性评估感知疼痛、阿片类药物和抗高血压药物使用以及血压的变化。结果:2例患者有常染色体显性多囊肾病病史(n = 2), 1例患者有腰痛血尿综合征(n = 1)。2例患者重做RDN。初步治疗后,两名患者的疼痛感减轻,阿片类药物的日剂量分别减少了50%和75%。一名患者感觉疼痛或阿片类药物的使用没有减少,并在3年后进行了重做手术,再次没有减少感觉疼痛或阿片类药物的使用。一名最初有反应的患者在2年后出现复发症状并接受了重做手术。3个月后,观察到疼痛和阿片类药物使用的显著改善。所有患者的平均24小时收缩压均下降,每次手术后平均下降12 mmHg。未观察到不良事件。结论:对于合并肾相关性疼痛综合征的高血压患者,经皮RDN可作为减轻疼痛严重程度和改善血压控制的替代治疗选择。初次缓解后症状复发的患者可考虑重做手术。
{"title":"Percutaneous renal denervation in the management of kidney-related pain syndromes: a case series","authors":"K.A. Saville ,&nbsp;V.J.M. Zeijen ,&nbsp;R. Zietse ,&nbsp;M. Salih ,&nbsp;D.A. Hesselink ,&nbsp;J. Daemen","doi":"10.1016/j.carrev.2025.04.041","DOIUrl":"10.1016/j.carrev.2025.04.041","url":null,"abstract":"<div><h3>Introduction</h3><div>Positive effects on pain reduction following renal denervation (RDN) have been described in patients with kidney-related pain syndromes, yet data on the safety and efficacy of redo RDN procedures are limited.</div></div><div><h3>Methods</h3><div>Consecutive patients with a history of chronic loin pain, hypertension and preserved renal function (eGFR ≥40 ml/min) scheduled for RDN were included. Changes in perceived pain, opioid and antihypertensive medication use, and blood pressure were prospectively assessed 3 months after each procedure.</div></div><div><h3>Results</h3><div>Two patients presented with a history of Autosomal Dominant Polycystic Kidney Disease (<em>n</em> = 2) and one with Loin Pain Hematuria Syndrome (<em>n</em> = 1). Two patients underwent a redo RDN. After the initial procedures, a reduction in perceived pain, along with a 50 % and 75 % reduction in the daily dosage of opioids, was observed in two patients. One patient showed no reduction in perceived pain or opioid use and underwent a redo procedure after 3 years, again with no reduction in perceived pain or opioid use. One patient who initially responded returned at 2 years with recurrent symptoms and underwent a redo procedure. After 3 months, a significant improvement in pain and opioid use was observed. Mean 24-hour systolic blood pressure decreased in all patients and after each procedure with a mean decrease of 12 mmHg. No adverse events were observed.</div></div><div><h3>Conclusion</h3><div>In hypertensive patients with kidney-related pain syndromes, percutaneous RDN may be considered as an alternative treatment option to reduce pain severity and improve blood pressure control. Redo procedures may be considered in patients with recurrent symptoms after an initial response.</div></div>","PeriodicalId":47657,"journal":{"name":"Cardiovascular Revascularization Medicine","volume":"82 ","pages":"Pages 15-20"},"PeriodicalIF":1.9,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143988230","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The role of Pulmonary Artery Pulsatility Index to assess the outcomes following catheter directed therapy in patients with intermediate-to-high and high-risk pulmonary embolism 肺动脉搏动指数在评估导管引导治疗中高、高危肺栓塞患者预后中的作用
IF 1.9 Q3 CARDIAC & CARDIOVASCULAR SYSTEMS Pub Date : 2026-01-01 DOI: 10.1016/j.carrev.2025.02.002
Mario Iannaccone , Sylwia Sławek-Szmyt , Marco Gamardella , Federica Fumarola , Riccardo Mangione , Daniele Savio , Filippo Russo , Giacomo Boccuzzi , Aleksander Araszkiewicz , Alaide Chieffo

Background

The clinical impact of catheter-directed therapy (CDT) for pulmonary embolism (PE) on right ventricular function and procedural outcomes remains undefined.

Methods

This observational retrospective study included consecutive patients who underwent CDT for PE at San Giovanni Bosco Hospital, Italy, and First Department of Cardiology, Poznan University Clinical Hospital, Poland, between 2021 and 2023. Clinical characteristics, PE risk stratification, pre and post-interventional invasive pulmonary artery pressure (PAP), and Pulmonary Artery Pulsatility Index (PAPi) were collected. The primary endpoint was in-hospital death.

Results

Among 165 patients (53 % male, mean age 63 ± 5.6 years), 65.6 % had multiple PE risk factors. 32.7 % were classified as high-risk (HR) PE, and 67.3 % as intermediate-high risk (IHR). Treatments included transcatheter thrombolysis (17 %), FlowTriever device (10 %), and Indigo Cath8 or Lightning 12 device (73 %), with 7 % requiring ECMO support. In IHR patients, mean PAP significantly decreased from 31.7 ± 7.1 to 23.4 ± 6.1 mmHg (p < 0.01) and PAPi from 3.1 ± 0.1 to 2.9 ± 0.1 (p < 0.01). HR patients had no significant changes in PAP or PAPi overall, but those who survived without events showed significant reductions in PAP (29.1 ± 8.7 to 23.8 ± 5.5, p < 0.02) and increases in PAPi (1.5 ± 0.6 to 2.0 ± 0.5, p < 0.01). In the HR group, a delta PAPi >0.45 predicted positive outcomes with 65.7 % sensitivity and 75 % specificity (AUC 0.83).

Conclusion

CDT for PE significantly impacts PAP and PAPi in acute PE patients. Normalization of PAPi in IHR patients and its increase in HR patients may indicate procedural success and right ventricular recovery. Hemodynamic changes could serve as important markers for procedural efficacy and outcome assessment in these groups.
背景:导管定向治疗(CDT)对肺栓塞(PE)的右心室功能和手术结果的临床影响尚不明确。方法:这项观察性回顾性研究纳入了2021年至2023年间在意大利San Giovanni Bosco医院和波兰波兹南大学临床医院第一心脏科接受CDT治疗PE的连续患者。收集临床特征、PE危险分层、介入前后有创肺动脉压(PAP)、肺动脉搏动指数(PAPi)。主要终点是院内死亡。结果:165例患者(男性53%,平均年龄63±5.6岁)中,65.6%存在多种PE危险因素。高危PE (HR)占32.7%,中高危PE (IHR)占67.3%。治疗包括经导管溶栓(17%)、FlowTriever装置(10%)和Indigo Cath8或Lightning 12装置(73%),其中7%需要ECMO支持。在IHR患者中,平均PAP从31.7±7.1显著下降到23.4±6.1 mmHg (p 0.45预测阳性结果,敏感性为65.7%,特异性为75% (AUC 0.83)。结论:PE CDT对急性PE患者PAP和PAPi有显著影响。IHR患者的PAPi正常化和HR患者的PAPi升高可能表明手术成功和右心室恢复。血流动力学变化可作为手术疗效和疗效评估的重要指标。
{"title":"The role of Pulmonary Artery Pulsatility Index to assess the outcomes following catheter directed therapy in patients with intermediate-to-high and high-risk pulmonary embolism","authors":"Mario Iannaccone ,&nbsp;Sylwia Sławek-Szmyt ,&nbsp;Marco Gamardella ,&nbsp;Federica Fumarola ,&nbsp;Riccardo Mangione ,&nbsp;Daniele Savio ,&nbsp;Filippo Russo ,&nbsp;Giacomo Boccuzzi ,&nbsp;Aleksander Araszkiewicz ,&nbsp;Alaide Chieffo","doi":"10.1016/j.carrev.2025.02.002","DOIUrl":"10.1016/j.carrev.2025.02.002","url":null,"abstract":"<div><h3>Background</h3><div>The clinical impact of catheter-directed therapy (CDT) for pulmonary embolism<span> (PE) on right ventricular function and procedural outcomes remains undefined.</span></div></div><div><h3>Methods</h3><div><span>This observational retrospective study included consecutive patients who underwent CDT for PE at San Giovanni Bosco Hospital, Italy, and First Department of Cardiology, Poznan University Clinical Hospital, Poland, between 2021 and 2023. Clinical characteristics, PE </span>risk stratification<span><span>, pre and post-interventional invasive pulmonary artery pressure (PAP), and Pulmonary Artery </span>Pulsatility Index (PAPi) were collected. The primary endpoint was in-hospital death.</span></div></div><div><h3>Results</h3><div>Among 165 patients (53 % male, mean age 63 ± 5.6 years), 65.6 % had multiple PE risk factors. 32.7 % were classified as high-risk (HR) PE, and 67.3 % as intermediate-high risk (IHR). Treatments included transcatheter thrombolysis (17 %), FlowTriever device (10 %), and Indigo Cath8 or Lightning 12 device (73 %), with 7 % requiring ECMO support. In IHR patients, mean PAP significantly decreased from 31.7 ± 7.1 to 23.4 ± 6.1 mmHg (p &lt; 0.01) and PAPi from 3.1 ± 0.1 to 2.9 ± 0.1 (p &lt; 0.01). HR patients had no significant changes in PAP or PAPi overall, but those who survived without events showed significant reductions in PAP (29.1 ± 8.7 to 23.8 ± 5.5, p &lt; 0.02) and increases in PAPi (1.5 ± 0.6 to 2.0 ± 0.5, p &lt; 0.01). In the HR group, a delta PAPi &gt;0.45 predicted positive outcomes with 65.7 % sensitivity and 75 % specificity (AUC 0.83).</div></div><div><h3>Conclusion</h3><div><span>CDT for PE significantly impacts PAP and PAPi in acute PE patients. Normalization of PAPi in IHR patients and its increase in HR patients may indicate procedural success and right ventricular recovery. </span>Hemodynamic changes could serve as important markers for procedural efficacy and outcome assessment in these groups.</div></div>","PeriodicalId":47657,"journal":{"name":"Cardiovascular Revascularization Medicine","volume":"82 ","pages":"Pages 57-61"},"PeriodicalIF":1.9,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143399282","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Intravascular ultrasound guidance for complex high-risk indicated procedures in underrepresented patient populations registry: Rationale and study design of the prospective observational IVUS CHIP UPP registry 在代表性不足的患者群体登记中,血管内超声指导复杂高危手术:前瞻性观察性IVUS CHIP UPP登记的基本原理和研究设计。
IF 1.9 Q3 CARDIAC & CARDIOVASCULAR SYSTEMS Pub Date : 2026-01-01 DOI: 10.1016/j.carrev.2025.06.027
Ernest Spitzer , Ximena S. Paredes , J. Dawn Abbott , Wayne B. Batchelor , Joost Daemen , Jan G.P. Tijssen , David E. Kandzari

Background

Intravascular ultrasound (IVUS) guidance during percutaneous coronary intervention (PCI) of complex coronary lesions is currently recommended by international guidelines. Complex coronary anatomy is observed in up to one third of the patients undergoing coronary interventions and is associated with worse clinical outcomes. Data on lesion characteristics and outcomes are scarce in census-defined minority groups.

Methods/design

The Intravascular Ultrasound Guidance for Complex High-Risk Indicated Procedures in Underrepresented Patient Populations (UPP) Registry is a prospective, observational, multicenter, single-arm study describing the safety and efficacy of IVUS-guided PCI in approximately 1010 subjects who self-identify within a demographic minority and undergo complex high-risk procedures. Criteria for optimal stenting include final minimal stent area (MSA) >5 mm2 or MSA >90 % of the distal reference lumen, plaque burden <50 % within 5 mm proximal or distal to stent edges, and absence of edge dissections involving the media and > 3 mm in length. The primary endpoint of target-vessel failure is a composite of cardiac death, target vessel myocardial infarction, or clinically indicated target-vessel revascularization at 1 year. Secondary endpoints include the individual components of the primary end point as well as procedural and imaging endpoints.

Summary

The IVUS CHIP UPP Registry is the first prospective investigation of procedural and clinical outcomes related to an IVUS-guided PCI for management of complex coronary lesions among minority patient populations in the United States.
背景:目前国际指南推荐在复杂冠状动脉病变经皮冠状动脉介入治疗(PCI)时血管内超声(IVUS)引导。在接受冠状动脉介入治疗的患者中,多达三分之一的患者存在复杂的冠状动脉解剖结构,这与较差的临床结果有关。在人口普查定义的少数群体中,关于病变特征和结果的数据很少。方法/设计:在代表性不足的患者群体(UPP)登记中,血管内超声指导复杂高风险指征手术是一项前瞻性、观察性、多中心、单臂研究,描述了ivus引导的PCI在大约1010名自认为属于人口统计学少数群体并接受复杂高风险手术的受试者中的安全性和有效性。最佳支架植入术的标准包括最终最小支架面积(MSA) >5 mm2或MSA >远端参考管腔的90%,斑块负荷长度为3 mm。靶血管衰竭的主要终点是心源性死亡、靶血管心肌梗死或1年后临床指示的靶血管重建术的复合终点。次要终点包括主要终点的各个组成部分以及手术终点和成像终点。摘要:IVUS CHIP UPP注册是美国少数患者中IVUS引导下PCI治疗复杂冠状动脉病变的程序和临床结果的第一个前瞻性调查。
{"title":"Intravascular ultrasound guidance for complex high-risk indicated procedures in underrepresented patient populations registry: Rationale and study design of the prospective observational IVUS CHIP UPP registry","authors":"Ernest Spitzer ,&nbsp;Ximena S. Paredes ,&nbsp;J. Dawn Abbott ,&nbsp;Wayne B. Batchelor ,&nbsp;Joost Daemen ,&nbsp;Jan G.P. Tijssen ,&nbsp;David E. Kandzari","doi":"10.1016/j.carrev.2025.06.027","DOIUrl":"10.1016/j.carrev.2025.06.027","url":null,"abstract":"<div><h3>Background</h3><div>Intravascular ultrasound<span> (IVUS) guidance during percutaneous coronary intervention (PCI) of complex coronary lesions is currently recommended by international guidelines. Complex coronary anatomy is observed in up to one third of the patients undergoing coronary interventions and is associated with worse clinical outcomes. Data on lesion characteristics and outcomes are scarce in census-defined minority groups.</span></div></div><div><h3>Methods/design</h3><div>The Intravascular Ultrasound Guidance for Complex High-Risk Indicated Procedures in Underrepresented Patient Populations (UPP) Registry is a prospective, observational, multicenter, single-arm study describing the safety and efficacy of IVUS-guided PCI in approximately 1010 subjects who self-identify within a demographic minority and undergo complex high-risk procedures. Criteria for optimal stenting include final minimal stent area (MSA) &gt;5 mm<sup>2</sup> or MSA &gt;90 % of the distal reference lumen, plaque burden &lt;50 % within 5 mm proximal or distal to stent edges, and absence of edge dissections involving the media and &gt; 3 mm in length. The primary endpoint of target-vessel failure is a composite of cardiac death, target vessel myocardial infarction, or clinically indicated target-vessel revascularization at 1 year. Secondary endpoints include the individual components of the primary end point as well as procedural and imaging endpoints.</div></div><div><h3>Summary</h3><div>The IVUS CHIP UPP Registry is the first prospective investigation of procedural and clinical outcomes related to an IVUS-guided PCI for management of complex coronary lesions among minority patient populations in the United States.</div></div>","PeriodicalId":47657,"journal":{"name":"Cardiovascular Revascularization Medicine","volume":"82 ","pages":"Pages 42-49"},"PeriodicalIF":1.9,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144498406","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Editorial: Impact of coronary intravascular lithotripsy on modern coronary revascularization 编辑:冠状动脉血管内碎石术对现代冠状动脉血运重建的影响。
IF 1.9 Q3 CARDIAC & CARDIOVASCULAR SYSTEMS Pub Date : 2026-01-01 DOI: 10.1016/j.carrev.2025.06.026
Wah Wah Htun
{"title":"Editorial: Impact of coronary intravascular lithotripsy on modern coronary revascularization","authors":"Wah Wah Htun","doi":"10.1016/j.carrev.2025.06.026","DOIUrl":"10.1016/j.carrev.2025.06.026","url":null,"abstract":"","PeriodicalId":47657,"journal":{"name":"Cardiovascular Revascularization Medicine","volume":"82 ","pages":"Pages 9-10"},"PeriodicalIF":1.9,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144555309","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Transcatheter treatment of tricuspid regurgitation: A state-of-the-art review 经导管治疗三尖瓣反流:最新进展。
IF 1.9 Q3 CARDIAC & CARDIOVASCULAR SYSTEMS Pub Date : 2026-01-01 DOI: 10.1016/j.carrev.2025.06.029
Claudio Sanfilippo , Marco Frazzetto , Michela Bonanni , Andrea Matteucci , Laura Anna Leo , Ridha Umar , Giuseppe Imperatore , Paulo de Coelho Castro , Guilherme Attizzani , Giuseppe Massimo Sangiorgi , Carmelo Grasso , Corrado Tamburino
Recent advancements in transcatheter techniques for the treatment of severe tricuspid regurgitation (TR) have introduced minimally invasive therapies with significantly lower risk profiles compared to traditional surgical approaches. Despite this progress, the latest European guidelines still recommend surgery as the “gold standard” for severe primary and secondary TR, particularly during left heart surgery or in cases with right ventricular dilation. However, surgical interventions are associated with high mortality and morbidity rates, making them less desirable for high-risk patients. As a result, transcatheter tricuspid valve interventions (TTVI) have emerged as promising alternatives, reshaping treatment paradigms. Among these, the tricuspid edge-to-edge repair (T-TEER) technique, using devices like the TriClip and PASCAL, has demonstrated significant clinical benefits, including improved valve function, symptom relief, and quality of life. While the TRI-SCORE and TRIVALVE risk scores help guide patient selection, further research is needed to refine outcomes across diverse clinical settings. Additionally, newer technologies like transcatheter valve replacement (TTVR) offer viable solutions for patients with complex anatomies. TTVR, exemplified by the EVOQUE valve, has shown promise in reducing TR and improving functional status, though it carries risks such as bleeding and pacemaker implantation. Moreover, heterotopic valve implantation, such as the TricValve, provides a less invasive option for symptom management, although it does not address the underlying valve pathology. Overall, the expanding range of transcatheter treatments is providing safer, effective alternatives for high-risk patients, with ongoing research critical to optimizing outcomes.
经导管技术治疗严重三尖瓣反流(TR)的最新进展引入了微创治疗,与传统手术方法相比,其风险显著降低。尽管取得了这些进展,最新的欧洲指南仍然推荐手术作为严重原发性和继发性TR的“金标准”,特别是在左心手术或右室扩张的情况下。然而,手术干预与高死亡率和发病率相关,使其不适合高危患者。因此,经导管三尖瓣介入治疗(TTVI)已成为有希望的替代方案,重塑了治疗范式。其中,使用TriClip和PASCAL等设备的三尖瓣边缘到边缘修复(T-TEER)技术已显示出显着的临床益处,包括改善瓣膜功能,症状缓解和生活质量。虽然TRI-SCORE和TRIVALVE风险评分有助于指导患者选择,但需要进一步的研究来完善不同临床环境下的结果。此外,像经导管瓣膜置换术(TTVR)这样的新技术为复杂解剖结构的患者提供了可行的解决方案。以EVOQUE瓣膜为代表的TTVR在减少TR和改善功能状态方面表现出了希望,尽管它存在出血和起搏器植入等风险。此外,异位瓣膜植入,如TricValve,为症状管理提供了一种侵入性较小的选择,尽管它不能解决潜在的瓣膜病理。总的来说,不断扩大的经导管治疗范围为高风险患者提供了更安全、有效的替代方案,正在进行的研究对优化结果至关重要。
{"title":"Transcatheter treatment of tricuspid regurgitation: A state-of-the-art review","authors":"Claudio Sanfilippo ,&nbsp;Marco Frazzetto ,&nbsp;Michela Bonanni ,&nbsp;Andrea Matteucci ,&nbsp;Laura Anna Leo ,&nbsp;Ridha Umar ,&nbsp;Giuseppe Imperatore ,&nbsp;Paulo de Coelho Castro ,&nbsp;Guilherme Attizzani ,&nbsp;Giuseppe Massimo Sangiorgi ,&nbsp;Carmelo Grasso ,&nbsp;Corrado Tamburino","doi":"10.1016/j.carrev.2025.06.029","DOIUrl":"10.1016/j.carrev.2025.06.029","url":null,"abstract":"<div><div><span>Recent advancements in transcatheter techniques for the treatment of severe tricuspid regurgitation (TR) have introduced </span>minimally invasive therapies<span><span><span> with significantly lower risk profiles compared to traditional surgical approaches. Despite this progress, the latest European guidelines still recommend surgery as the “gold standard” for severe primary and secondary TR, particularly during left heart surgery or in cases with right ventricular dilation. However, surgical interventions are associated with high mortality and morbidity rates, making them less desirable for high-risk patients. As a result, transcatheter tricuspid valve<span> interventions (TTVI) have emerged as promising alternatives, reshaping treatment paradigms. Among these, the tricuspid edge-to-edge repair (T-TEER) technique, using devices like the TriClip and PASCAL, has demonstrated significant clinical benefits, including improved valve function, symptom relief, and quality of life<span>. While the TRI-SCORE and TRIVALVE risk scores help guide patient selection, further research is needed to refine outcomes across diverse clinical settings. Additionally, newer technologies like transcatheter valve replacement (TTVR) offer viable solutions for patients with complex anatomies. TTVR, exemplified by the EVOQUE valve, has shown promise in reducing TR and improving functional status, though it carries risks such as bleeding and </span></span></span>pacemaker implantation. Moreover, </span>heterotopic valve implantation, such as the TricValve, provides a less invasive option for symptom management, although it does not address the underlying valve pathology. Overall, the expanding range of transcatheter treatments is providing safer, effective alternatives for high-risk patients, with ongoing research critical to optimizing outcomes.</span></div></div>","PeriodicalId":47657,"journal":{"name":"Cardiovascular Revascularization Medicine","volume":"82 ","pages":"Pages 129-135"},"PeriodicalIF":1.9,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144568001","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Transcatheter aortic valve replacement in small aortic annuli: A propensity-matched comparison between intra-annular self-expanding valves and balloon-expandable valves 经导管主动脉瓣置换术治疗小主动脉环:环内自膨胀瓣膜与球囊膨胀瓣膜的倾向匹配比较
IF 1.9 Q3 CARDIAC & CARDIOVASCULAR SYSTEMS Pub Date : 2026-01-01 DOI: 10.1016/j.carrev.2025.05.009
Danial Ahmad , Michel Pompeu Sá , Dustin Kliner , Derek Serna-Gallegos , Catalin Toma , Amber Makani , David West , Yisi Wang , Floyd Thoma , Takuya Ogami , Irsa Hasan , Ibrahim Sultan

Background

Specific transcatheter aortic valve replacement (TAVR) valve superiority is not established in the small aortic annulus (SAA) population. We sought to compare clinical and echocardiographic characteristics between patients with a SAA who underwent TAVR with either intra-annular self-expanding valves (SEV) or balloon-expandable valves (BEV).

Methods

This was an observational, retrospective analysis (2013−2023). SAA was defined as an aortic annulus diameter < 23 mm (maximum) and annulus area ≤ 430 mm2. Unmatched and propensity-score matched (PSM) populations were compared.

Results

We identified 663 patients with SAA who underwent TAVR with SEV (n = 106) or BEV (n = 557). The PSM cohort (96 pairs) was predominantly female (90.6 % and 87.5 %) with a median age of 82.5 and 81.0 years. No statistically significant differences were observed in VARC-3 outcomes (periprocedural mortality, technical success, device success, clinical efficacy). Higher rates of residual mean gradients >20 mmHg were seen in the BEV group at 30 days (SEV 2.1 % vs BEV 21.9 %, P < 0.001) as well as lower median values of indexed effective orifice area (SEV 0.9 vs 0.6 cm2/m2). Severe PPM was also more common in the BEV group (SEV 5.2 % vs BEV 21.9 %, P = 0.002). At 2 years, differences in the rates of all-cause death (SE 11.9 % vs BE 17.1 %, Plog-rank = 0.6794) and stroke (SEV 3.4 % vs BEV 10.2 %, P = 0.7055) were not statistically significant.

Conclusions

Intra-annular SEV presented better hemodynamics compared to BEV; however, survival and incidence of stroke were comparable between the groups at 2 years. Potential risk of nonstructural valve deterioration with BEV needs further investigation with longer follow-up.
背景:特异性经导管主动脉瓣置换术(TAVR)在小主动脉环(SAA)人群中的优势尚未确立。我们试图比较接受TAVR的SAA患者的临床和超声心动图特征,无论是环内自扩瓣膜(SEV)还是球囊可扩瓣膜(BEV)。方法:采用观察性、回顾性分析(2013-2023)。SAA定义为主动脉环直径2。不匹配和倾向分数匹配(PSM)人群进行比较。结果:我们发现663例SAA患者接受了伴有SEV (n = 106)或BEV (n = 557)的TAVR。PSM队列(96对)以女性为主(90.6%和87.5%),中位年龄分别为82.5岁和81.0岁。在VARC-3结局(围手术期死亡率、技术成功、器械成功、临床疗效)方面没有观察到统计学上的显著差异。在30天,BEV组观察到较高的残余平均梯度率bb0 20 mmHg (SEV 2.1% vs BEV 21.9%, P 2/m2)。严重PPM在BEV组中也更为常见(SEV 5.2% vs BEV 21.9%, P = 0.002)。2年时,全因死亡率(SE 11.9% vs BE 17.1%, Plog-rank = 0.6794)和卒中(SEV 3.4% vs BEV 10.2%, P = 0.7055)的差异无统计学意义。结论:与BEV相比,环内SEV具有更好的血流动力学;然而,两组在2年时的生存率和卒中发生率是相当的。BEV非结构性瓣膜恶化的潜在风险需要进一步调查,随访时间更长。
{"title":"Transcatheter aortic valve replacement in small aortic annuli: A propensity-matched comparison between intra-annular self-expanding valves and balloon-expandable valves","authors":"Danial Ahmad ,&nbsp;Michel Pompeu Sá ,&nbsp;Dustin Kliner ,&nbsp;Derek Serna-Gallegos ,&nbsp;Catalin Toma ,&nbsp;Amber Makani ,&nbsp;David West ,&nbsp;Yisi Wang ,&nbsp;Floyd Thoma ,&nbsp;Takuya Ogami ,&nbsp;Irsa Hasan ,&nbsp;Ibrahim Sultan","doi":"10.1016/j.carrev.2025.05.009","DOIUrl":"10.1016/j.carrev.2025.05.009","url":null,"abstract":"<div><h3>Background</h3><div>Specific transcatheter aortic valve replacement (TAVR) valve superiority is not established in the small aortic annulus (SAA) population. We sought to compare clinical and echocardiographic characteristics between patients with a SAA who underwent TAVR with either intra-annular self-expanding valves (SEV) or balloon-expandable valves (BEV).</div></div><div><h3>Methods</h3><div>This was an observational, retrospective analysis (2013−2023). SAA was defined as an aortic annulus diameter &lt; 23 mm (maximum) and annulus area ≤ 430 mm<sup>2</sup>. Unmatched and propensity-score matched (PSM) populations were compared.</div></div><div><h3>Results</h3><div>We identified 663 patients with SAA who underwent TAVR with SEV (<em>n</em> = 106) or BEV (<em>n</em> = 557). The PSM cohort (96 pairs) was predominantly female (90.6 % and 87.5 %) with a median age of 82.5 and 81.0 years. No statistically significant differences were observed in VARC-3 outcomes (periprocedural mortality, technical success, device success, clinical efficacy). Higher rates of residual mean gradients &gt;20 mmHg were seen in the BEV group at 30 days (SEV 2.1 % vs BEV 21.9 %, <em>P</em> &lt; 0.001) as well as lower median values of indexed effective orifice area (SEV 0.9 vs 0.6 cm<sup>2</sup>/m<sup>2</sup>). Severe PPM was also more common in the BEV group (SEV 5.2 % vs BEV 21.9 %, <em>P</em> = 0.002). At 2 years, differences in the rates of all-cause death (SE 11.9 % vs BE 17.1 %, P<sub>log-rank</sub> = 0.6794) and stroke (SEV 3.4 % vs BEV 10.2 %, <em>P</em> = 0.7055) were not statistically significant.</div></div><div><h3>Conclusions</h3><div>Intra-annular SEV presented better hemodynamics<span> compared to BEV; however, survival and incidence of stroke were comparable between the groups at 2 years. Potential risk of nonstructural valve deterioration with BEV needs further investigation with longer follow-up.</span></div></div>","PeriodicalId":47657,"journal":{"name":"Cardiovascular Revascularization Medicine","volume":"82 ","pages":"Pages 78-83"},"PeriodicalIF":1.9,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144081332","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Cardiovascular Revascularization Medicine
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1